Le Lézard
Classified in: Health
Subjects: RCL, PSF, CFG

Advisory - One lot of pms-PROGESTERONE 100 mg capsules recalled because it may pose serious risks to individuals with severe peanut allergies


OTTAWA, ON, Aug. 24, 2021 /CNW/ -

Summary

Issue
Pharmascience Inc. is recalling one lot (1318593, expiry 10/2022) of pms-PROGESTERONE 100 mg capsules because the bottles may contain Akorn 100 mg progesterone gelatin capsules in addition to or instead of the intended pms-PROGESTERONE 100 mg gelatin capsules. The Akorn capsules contain peanut oil, an ingredient that is not listed on the label of pms-PROGESTERONE 100 mg capsules. Peanuts may cause life-threatening allergic reactions (anaphylaxis) in individuals with severe peanut allergies.

pms-PROGESTERONE is a prescription hormone drug used as part of hormone replacement therapy for menopause in women.

The pms-PROGESTERONE 100 mg capsules are round and beige with "100" printed in black on the capsule, while the Akorn 100 mg progesterone capsules are round and pink with "AK" printed in black on the capsule.

The Pharmascience and Akorn capsules contain the same dose of the active ingredient, progesterone. Akorn 100 mg progesterone capsule is not authorized for sale in Canada and therefore it has not been reviewed by Health Canada for its safety, efficacy and quality.

Health Canada is monitoring the recall. If additional safety information is identified, Health Canada will take appropriate action and inform Canadians as needed.

Affected products

Company

Product

DIN

Lot

Expiry

Pharmascience Inc.

pms-PROGESTERONE 100 mg capsules

100-capsule bottles

02476576

1318593

10/2022

What you should do

pms-PROGESTERONE 100 mg capsules, bottle of 100 capsules, DIN 02476576 (CNW Group/Health Canada)

pms-PROGESTERONE 100 mg capsules are beige and marked with

Akorn 100 mg progesterone capsules are pink and marked with

Également disponible en français

SOURCE Health Canada


These press releases may also interest you

at 06:03
The IAMStm brand, proudly part of the Mars family of brands, announced today the launch of the IAMStm Puppy Hub and Kitten Hub, two online tools featuring expert knowledge and advice for new and soon-to-be pet parents. Each Hub will bring...

at 06:00
Today, TELUS Health announced a collaboration with Nova Scotia Health (NSH) to enable residents of Nova Scotia to access their primary care information through the YourHealthNS app. This health data interoperability initiative marks the first...

at 05:30
The global Digital Healthcare Market, valued at $220.10 billion in 2024, is on a trajectory of rapid expansion, with projections indicating it will soar to $836.10 billion by 2031, growing at a compound annual growth rate (CAGR) of 21% from 2024 to...

at 05:09
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period. The...

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...



News published on and distributed by: